Combining-Gabapentin-Topiramate

From Psychiatrienet
Revision as of 12:02, 21 April 2010 by Ashni (talk | contribs)
Jump to: navigation, search
Gabapentin
Type moodstabilizer
Group anticonvulsant
links
ATC-code N03AX12
PubChem 3446
PubMed Gabapentin
Drugs.com gabapentin
Kompas (Dutch) Gabapentin
Wikipedia Gabapentin
Topiramate
Type moodstabilizer
Group anticonvulsant
links
ATC-code N03AX11
PubChem 5284627
PubMed Topiramate
Drugs.com topiramate
Kompas (Dutch) Topiramate
Wikipedia Topiramate

Adding topiramate to gabapentin.

Infobord.png General information
  • Gabapentin is eliminated unchanged by the kidney for 100%.
  • Topiramate induces CYP3A4 and is an inhibitor of CYP2C19.
  • Gabapentine is eliminated unchanged by the kidney for 100%. Changes in the rate of excretion can cause unwanted effects.
  • Topiramate induces CYP3A4 and is an inhibiter of CYP2C19.
  • This combination of drugs may have possible synergistic effects. However, the pharmacokinetic drug interactions will influence the plasma levels. Dose adaptation is recommended for this combination. [2]
Eenrichtingbord.png Start topiramate
  • Start topiramate according to the general dosing advice.



  1. 1.0 1.1 1.2 Farmacotherapeutisch Kompas - gabapentine (dutch) Cite error: Invalid <ref> tag; name "ftk" defined multiple times with different content Cite error: Invalid <ref> tag; name "ftk" defined multiple times with different content
  2. Freeman et al. Mood stabilizer Combinations: A Review of Safety and Efficacy. Am J Psychiatry 1998;155:12-21
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.